161 related articles for article (PubMed ID: 38495183)
1. Identification of bioactive compounds of
Afzal M; Qais FA; Abduh NAY; Christy M; Ayub R; Alarifi A
Heliyon; 2024 Mar; 10(5):e27361. PubMed ID: 38495183
[TBL] [Abstract][Full Text] [Related]
2. Structure-Guided Approach to Discover Tuberosin as a Potent Activator of Pyruvate Kinase M2, Targeting Cancer Therapy.
Adnan M; Shamsi A; Elasbali AM; Siddiqui AJ; Patel M; Alshammari N; Alharethi SH; Alhassan HH; Bardakci F; Hassan MI
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361954
[TBL] [Abstract][Full Text] [Related]
3. In-Silico Analysis of Phytocompounds of
Qais FA; Alomar SY; Imran MA; Hashmi MA
Molecules; 2022 Sep; 27(18):. PubMed ID: 36144527
[TBL] [Abstract][Full Text] [Related]
4. Identification of Natural Compounds as Inhibitors of Pyruvate Kinase M2 for Cancer Treatment.
Sarfraz I; Rasul A; Jabeen F; Sultana T; Adem Ş
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296707
[TBL] [Abstract][Full Text] [Related]
5. Roadmap to Pyruvate Kinase M2 Modulation - A Computational Chronicle.
Kapoor S; Chatterjee DR; Chowdhury MG; Das R; Shard A
Curr Drug Targets; 2023; 24(6):464-483. PubMed ID: 36998144
[TBL] [Abstract][Full Text] [Related]
6. In silico investigation of potential pyruvate kinase M2 regulators from traditional Chinese medicine against cancers.
Chen KC; Chen KB; Chen HY; Chen CY
Biomed Res Int; 2014; 2014():189495. PubMed ID: 25089263
[TBL] [Abstract][Full Text] [Related]
7. Discovery of boronic acid-based potent activators of tumor pyruvate kinase M2 and development of gastroretentive nanoformulation for oral dosing.
Patle R; Shinde S; Patel S; Maheshwari R; Jariyal H; Srivastava A; Chauhan N; Globisch C; Jain A; Tekade RK; Shard A
Bioorg Med Chem Lett; 2021 Jun; 42():128062. PubMed ID: 33901643
[TBL] [Abstract][Full Text] [Related]
8. Spectroscopic insights with molecular docking and molecular dynamic simulation studies of anticancer drug 5-Fluorouracil targeting human pyruvate kinase m2.
Priyadarshinee M; Dehury B; Mishra S; Jena C; Patra M; Mishra NK; Samanta L; Mallick BC
J Biomol Struct Dyn; 2024 Feb; ():1-13. PubMed ID: 38345048
[TBL] [Abstract][Full Text] [Related]
9. LC-MS characterized methanolic extract of zanthoxylum armatum possess anti-breast cancer activity through Nrf2-Keap1 pathway: An in-silico, in-vitro and in-vivo evaluation.
Sahu R; Kar RK; Sunita P; Bose P; Kumari P; Bharti S; Srivastava S; Pattanayak SP
J Ethnopharmacol; 2021 Apr; 269():113758. PubMed ID: 33359860
[TBL] [Abstract][Full Text] [Related]
10. Identification of a new pyruvate kinase M2 isoform (PKM2) activator for the treatment of non-small-cell lung cancer (NSCLC).
Li RZ; Fan XX; Shi DF; Zhu GY; Wang YW; Luo LX; Pan HD; Yao XJ; Leung EL; Liu L
Chem Biol Drug Des; 2018 Nov; 92(5):1851-1858. PubMed ID: 29931766
[TBL] [Abstract][Full Text] [Related]
11. Integrated In Silico-In Vitro Discovery of Lung Cancer-related Tumor Pyruvate Kinase M2 (PKM2) Inhibitors.
Ye X; Sun Y; Xu Y; Chen Z; Lu S
Med Chem; 2016; 12(7):613-620. PubMed ID: 26951145
[TBL] [Abstract][Full Text] [Related]
12. Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator.
Matsui Y; Yasumatsu I; Asahi T; Kitamura T; Kanai K; Ubukata O; Hayasaka H; Takaishi S; Hanzawa H; Katakura S
Bioorg Med Chem; 2017 Jul; 25(13):3540-3546. PubMed ID: 28511909
[TBL] [Abstract][Full Text] [Related]
13. Combining structure-based pharmacophore modeling, virtual screening, and in silico ADMET analysis to discover novel tetrahydro-quinoline based pyruvate kinase isozyme M2 activators with antitumor activity.
Chen C; Wang T; Wu F; Huang W; He G; Ouyang L; Xiang M; Peng C; Jiang Q
Drug Des Devel Ther; 2014; 8():1195-210. PubMed ID: 25214764
[TBL] [Abstract][Full Text] [Related]
14. Novel Specific Pyruvate Kinase M2 Inhibitor, Compound 3h, Induces Apoptosis and Autophagy through Suppressing Akt/mTOR Signaling Pathway in LNCaP Cells.
Jiang C; Zhao X; Jeong T; Kang JY; Park JH; Kim IS; Kim HS
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612260
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis and Biological Evaluation of Quinoline-8-Sulfonamides as Inhibitors of the Tumor Cell-Specific M2 Isoform of Pyruvate Kinase: Preliminary Study.
Marciniec K; Rzepka Z; Chrobak E; Boryczka S; Latocha M; Wrześniok D; Beberok A
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985481
[TBL] [Abstract][Full Text] [Related]
16. Knowledge-driven design and optimization of potent symmetric anticancer molecules: A case study on PKM2 activators.
Jaiswal E; Globisch C; Jain A
Comput Biol Med; 2022 Dec; 151(Pt B):106313. PubMed ID: 36450217
[TBL] [Abstract][Full Text] [Related]
17. Detection of Nail Oncometabolite SAICAR in Oral Cancer Patients and Its Molecular Interactions with PKM2 Enzyme.
Patel R; Raj AK; Lokhande KB; Almasri MA; Alzahrani KJ; Almeslet AS; Swamy KV; Sarode GS; Sarode SC; Patil S; Sharma NK
Int J Environ Res Public Health; 2021 Oct; 18(21):. PubMed ID: 34769743
[TBL] [Abstract][Full Text] [Related]
18. A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
Arora S; Joshi G; Chaturvedi A; Heuser M; Patil S; Kumar R
J Med Chem; 2022 Jan; 65(2):1171-1205. PubMed ID: 34726055
[TBL] [Abstract][Full Text] [Related]
19. Pyruvate Kinase M2 and Cancer: The Role of PKM2 in Promoting Tumorigenesis.
Zahra K; Dey T; Ashish ; Mishra SP; Pandey U
Front Oncol; 2020; 10():159. PubMed ID: 32195169
[TBL] [Abstract][Full Text] [Related]
20. New pyridin-3-ylmethyl carbamodithioic esters activate pyruvate kinase M2 and potential anticancer lead compounds.
Zhang Y; Liu B; Wu X; Li R; Ning X; Liu Y; Liu Z; Ge Z; Li R; Yin Y
Bioorg Med Chem; 2015 Aug; 23(15):4815-4823. PubMed ID: 26081759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
